Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer's Disease beta Secretase, BACE1

Mycroft-West, Courtney J, Devlin, Anthony J, Cooper, Lynsay C, Guimond, Scott E, Procter, Patricia, Guerrini, Marco, Miller, Gavin J, Fernig, David G ORCID: 0000-0003-4875-4293, Yates, Edwin A ORCID: 0000-0001-9365-5433, Lima, Marcelo A
et al (show 1 more authors) (2021) Glycosaminoglycans from Litopenaeus vannamei Inhibit the Alzheimer's Disease beta Secretase, BACE1. MARINE DRUGS, 19 (4). 203-.

Access the full-text of this item by clicking on the Open Access link.


Only palliative therapeutic options exist for the treatment of Alzheimer's Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer's Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer's disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp Litopenaeus vannamei, was found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered.

Item Type: Article
Uncontrolled Keywords: Alzheimer&#8217, s disease, amyloid-&#946, BACE1, &#946, -secretase, glycosaminoglycan, chondroitin sulfate, heparin, heparan sulphate, Litopenaeus vannamei
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 07 Jul 2021 10:06
Last Modified: 18 Jan 2023 21:36
DOI: 10.3390/md19040203
Open Access URL:
Related URLs: